https://cllupdate.it/sample-page/2020-11-19T16:24:41+00:00https://cllupdate.it/privacy-policy/2021-02-12T15:20:40+00:00https://cllupdate.it/2022-03-24T08:14:38+00:00https://cllupdate.it/user/2020-12-20T08:01:54+00:00https://cllupdate.it/login/2020-12-20T08:01:54+00:00https://cllupdate.it/register/2021-01-28T11:13:53+00:00https://cllupdate.it/members/2020-12-20T08:01:54+00:00https://cllupdate.it/logout/2020-12-20T08:01:54+00:00https://cllupdate.it/account/2020-12-20T08:01:54+00:00https://cllupdate.it/password-reset/2020-12-20T08:01:54+00:00https://cllupdate.it/cllupdate-the-project/2022-03-24T08:41:10+00:00https://cllupdate.it/faculty/2022-03-24T08:41:38+00:00https://cllupdate.it/lassociazione-obinutuzumab-ibrutinib-venetoclax-ivo-a-durata-fissa-per-14-mesi-offre-vantaggi-in-termini-di-risposte-globali-e-umrd-mrd-non-rilevabile-durature-a-36-mesi-nei-pazienti/2021-02-17T09:44:40+00:00https://cllupdate.it/venetoclax-e-rituximab-vr-a-durata-fissa-di-24-mesi-confermano-il-beneficio-a-lungo-termine-nei-pazienti-con-llc-e-malattia-recidiva-refrattaria-r-r-kater-et-al-ash-meeting-2020-presentation/2021-02-18T13:36:36+00:00https://cllupdate.it/efficacia-promettente-di-car-t-liso-cel-in-combinazione-con-ibrutinib-in-paziente-fortemente-pretrattati-con-leucemia-linfatica-cronica-e-che-avevano-fallito-ibrutinib-studio-di-fase-i-ii-transcend-c/2021-03-08T15:31:57+00:00https://cllupdate.it/la-risposta-a-ibrutinib-venetoclax-iv-in-pazienti-con-llc-recidiva-refrattaria-r-r-e-mantenuta-nonostante-la-sospensione-del-trattamento-nei-pazienti-mrd-a-38-mesi-munir-et-al-ash-meeting/2021-02-17T09:47:22+00:00https://cllupdate.it/unit-1-cll-educational-road-map/2021-02-16T11:28:03+00:00https://cllupdate.it/cookie-policy/2021-02-12T15:20:26+00:00https://cllupdate.it/terapia-a-termine-con-venetoclax-e-rituximab-venr-in-prima-linea-in-pazienti-giovani-ad-alto-rischio-biologico-i-risultati-preliminari-supportano-lefficacia-della-combinazione-studio-gimema-ve/2021-03-16T14:34:04+00:00https://cllupdate.it/laggiunta-di-venetoclax-come-consolidamento-alla-terapia-con-ibrutinib-consente-di-ottenere-un-alto-tasso-di-malattia-residua-minima-non-rilevabile-nei-pazienti-con-cll-ad-alto-rischio-thompson-et/2021-04-01T10:34:22+00:00https://cllupdate.it/la-combinazione-di-venetoclax-e-ibrutinib-in-prima-linea-conferisce-alti-tassi-di-mrd-non-rilevabile-e-sopravvivenza-libera-da-malattia-senza-ulteriore-trattamento-nei-pazienti-con-cll-wierda-et-al/2021-03-16T14:32:36+00:00https://cllupdate.it/combinazione-di-venetoclax-e-obinutuzumab-per-12-mesi-in-prima-linea-cll14-il-follow-up-a-4-anni-dimostra-una-dinamica-di-negativizzazione-di-mrd-che-si-traduce-in-risultati-molto-significativi-o/2021-03-16T14:35:05+00:00https://cllupdate.it/unit-2-cll-educational-road-map/2021-03-16T14:47:05+00:00https://cllupdate.it/cll-e-covid-informazioni-preliminari/2021-04-13T08:30:55+00:00https://cllupdate.it/autoformazione-ecm/2021-04-21T07:20:38+00:00https://cllupdate.it/unit-4-cll-educational-road-map/2021-05-06T16:21:10+00:00https://cllupdate.it/cll-e-covid-raccomandazioni-linee-guida-e-vaccini/2021-05-06T15:32:14+00:00https://cllupdate.it/efficacia-del-vaccino-bnt162b2-nei-pazienti-con-cll-yair-herishanu-et-al-blood-2021/2021-05-27T09:46:39+00:00https://cllupdate.it/survey-sul-trattamento-in-prima-linea-della-cll-in-europa-smoley-l-et-al-oral-presentation-iwcll-2021/2021-11-09T14:45:40+00:00https://cllupdate.it/efficacia-dellassociazione-venetoclax-ibrutinib-a-durata-fissa-studio-captivate-allan-j-et-al-eha-meeting-2021/2021-08-04T09:52:25+00:00https://cllupdate.it/efficacia-e-sicurezza-della-terapia-con-acalabrutinib-sono-mantenute-a-4-anni-sharman-j-et-al-eha-meeting-2021/2021-08-04T09:52:23+00:00https://cllupdate.it/unit-6-cll-educational-road-map/2021-08-03T15:32:21+00:00https://cllupdate.it/migliore-efficacia-e-profilo-di-tossicita-di-zanubrutinib-rispetto-a-ibrutinib-in-pazienti-con-cll-r-r-studio-alpine-hillmen-p-et-al-eha-meeting-2021/2021-08-06T13:11:14+00:00https://cllupdate.it/acalabrutinib-rispetto-a-ibrutinib-mostra-la-stessa-efficacia-con-minore-tossicita-cardiovascolare-nei-pazienti-con-cll-r-r-studio-elevate-r-r-hillmen-p-et-al-eha-meeting-2021/2021-08-06T13:11:32+00:00https://cllupdate.it/unit-7-cll-educational-road-map/2021-08-06T12:12:51+00:00https://cllupdate.it/il-follow-up-a-4-anni-conferma-il-beneficio-a-lungo-termine-del-trattamento-di-durata-fissa-di-12-mesi-con-venetoclax-e-obinutuzumab-ven-obi-in-pazienti-in-prima-linea-con-cllstudio-cll14-al/2021-09-28T12:44:15+00:00https://cllupdate.it/malattia-residua-misurabile-nella-leucemia-linfatica-cronica-revisione-di-esperti-e-raccomandazioni/2021-09-27T09:11:34+00:00https://cllupdate.it/watch-wait-nella-cll/2021-11-09T16:09:56+00:00https://cllupdate.it/unit-10-cll-educational-road-map/2021-12-14T14:47:32+00:00https://cllupdate.it/studio-gimema-veritas-venetoclax-e-rituximab-front-line-elevata-percentuale-di-risposta-in-assenza-di-malattia-residuamauro-fr-congresso-nazionale-sie-2021/2021-12-14T15:43:13+00:00https://cllupdate.it/trattamento-personalizzato-guidato-dalla-mrd-con-laggiunta-sequenziale-di-ibrutinib-al-venetoclax-improve-studyscarfo-l-et-al-congresso-nazionale-sie-2021/2021-12-14T14:41:50+00:00https://cllupdate.it/obinutuzumab-chlorambucil-vs-ibrutinib-in-pazienti-precedentemente-non-trattati-senza-interruzione-tp53-cll-campus-studyvisentin-a-et-al-congresso-nazionale-sie-2021/2021-12-14T14:58:54+00:00https://cllupdate.it/infezioni-nella-cll/2021-12-22T14:48:15+00:00https://cllupdate.it/dichiarazione-accessibilita/2025-08-02T13:01:22+00:00